GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, ...

Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

GSK is funding public health organizations working to address US adult immunization gaps and increase community vaccine education, outreach and access These grants are part of GSK’s COiMMUNITY ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing respiratory syncytial virus (RSV) vaccines, according to a filing made in Delaware ...

Amid the current market turmoil, it is worth remembering that the pharmaceutical industry must continue its normal business of ensuring that it has products to sell in 10 years, with GSK (GSK) signing ...

AstraZeneca dropped 6.80% GlaxoSmithKline (GSK) dropped by 5.48% Novo Nordisk - which produces weight-loss drugs Ozempic and Wegovy - has fallen 6.93% The trade in goods between the two economic ...

This year, Professor Doryen Bubeck of Imperial's Department of Life Sciences has won the GlaxoSmithKline Award which is given in recognition of research leading to new advances in medical science by a ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Upendra Singh, Commercial Head - General Medicines, effective from the close of business hours of 18th April 2025.

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...

LOS ANGELES, April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK plc ("GSK" or "the Company ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier. GSK is fronting £38.5 million (nearly $50 million), in a partnership with ...